New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
10:55 EDTKITD, KITD, CDTI, CDTI, ICUI, ICUI, STMP, STMP, XPL, XPL, XRS, XRS, YOD, YOD, COA, COA, HZNP, HZNP, ICPW, ICPW, BDSI, BDSIRoth Capital to host a conference
25th Annual Roth Conference is being held in Dana Point, California on March 17-20 with webcasted company presentations to begin on March 18 at 11 am; not all company presentations may be webcasted. Webcast Link
News For KITD;ICPW;HZNP;COA;YOD;XRS;XPL;STMP;ICUI;CDTI;BDSI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:22 EDTHZNPHorizon Pharma granted Notice of Allowance for Pennsaid by USPTO
Subscribe for More Information
August 21, 2015
13:04 EDTHZNPDepomed to file revocation statement with SEC
Subscribe for More Information
August 20, 2015
07:03 EDTHZNPHorizon Pharma issued Notice of Allowance by USPTO covering Vimovo
Subscribe for More Information
August 19, 2015
17:40 EDTHZNPDepomed sends letter to Horizon Pharma CEO
Subscribe for More Information
17:36 EDTHZNPDepomed board unanimously rejects revised proposal from Horizon Pharma
Subscribe for More Information
August 13, 2015
14:06 EDTHZNPDepomed says Horizon proposal has current value below $31 per share
Subscribe for More Information
09:20 EDTBDSIOn The Fly: Pre-market Movers
Subscribe for More Information
07:07 EDTBDSIBioDelivery Sciences' new Onsolis formulation approved by FDA
BioDelivery Sciences announced the approval by the FDA of a Supplemental New Drug Application for a new formulation of Onsolis CII for the management of breakthrough pain in patients with cancer who are opioid tolerant. The new formulation was submitted to address previously announced appearance-related changes. Early this year, BDSI entered into an assignment and revenue sharing agreement with its partner for Onsolis, Meda Pharmaceuticals, to return the marketing authorization back to BDSI and the right to seek marketing authorizations for Onsolis in the U.S., Canada and Mexico. Meda retains the rights to Onsolis outside the U.S., where it is marketed in the E.U. as Breakyl. Onsolis is separately licensed by BDSI in Taiwan and South Korea.
07:03 EDTYODYOU On Demand reports Q2 EPS (6c) vs. (5c) last year
Reports Q2 revenue $1.48M vs. 183K last year. The increase in revenue was primarily attributable to the growth in the video streaming business on mobile and Over-The-Top platforms.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use